SWOG-S2104: Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors

Objective

This phase II trial studies the effect of capecitabine and temozolomide after surgery in treating patients with high-risk well-differentiated pancreatic neuroendocrine tumors. Chemotherapy drugs, such as capecitabine and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving capecitabine and temozolomide after surgery could prevent or delay the return of cancer in patients with high-risk well-differentiated pancreatic neuroendocrine tumors.

National Clinical Trial (NCT) Number: 05040360

National Library of Medicine clinicaltrials.gov Website Address: https://clinicaltrials.gov/study/NCT05040360

Location: Essentia Health Cancer Centers

Research Study Categories

• Adult Oncology Studies

Specialties

• Gastrointestinal Cancer

Contact

Cancer Clinical Trials at 218-786-3308 or 844-681-7944, [email protected]